Neumora Therapeutics’ (NMRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Neumora Therapeutics (NASDAQ:NMRA) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. HC Wainwright also issued estimates for Neumora Therapeutics’ Q1 2025 earnings at ($0.46) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS and Q4 2025 earnings at ($0.44) EPS.

A number of other research firms have also weighed in on NMRA. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $23.40.

Neumora Therapeutics Price Performance

Shares of NMRA stock opened at $10.18 on Monday. The company has a fifty day moving average price of $11.80 and a two-hundred day moving average price of $11.53. Neumora Therapeutics has a one year low of $8.33 and a one year high of $21.00. The stock has a market cap of $1.64 billion, a P/E ratio of -5.44 and a beta of 3.34.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter last year, the business posted ($1.14) EPS. As a group, equities research analysts anticipate that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Insider Buying and Selling at Neumora Therapeutics

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $17.03, for a total value of $239,254.47. Following the transaction, the director now directly owns 20,100 shares of the company’s stock, valued at $342,303. This trade represents a 41.14 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Robert A. Lenz sold 5,563 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the transaction, the insider now owns 322,966 shares of the company’s stock, valued at approximately $4,847,719.66. This represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.40% of the company’s stock.

Institutional Trading of Neumora Therapeutics

Large investors have recently bought and sold shares of the business. Amalgamated Bank lifted its holdings in shares of Neumora Therapeutics by 472.8% in the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after acquiring an additional 2,402 shares during the last quarter. Handelsbanken Fonder AB increased its position in Neumora Therapeutics by 35.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after purchasing an additional 6,900 shares in the last quarter. Quarry LP acquired a new position in Neumora Therapeutics during the 2nd quarter worth approximately $98,000. Intech Investment Management LLC bought a new position in Neumora Therapeutics in the 3rd quarter valued at approximately $175,000. Finally, Ballentine Partners LLC acquired a new stake in Neumora Therapeutics in the third quarter valued at approximately $178,000. 47.65% of the stock is owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.